{"schema_version":"secwatch.filing_event.v1","accession":"0000064803-26-000097","form_type":"8-K","ticker":"CVS","cik":"0000064803","company_name":"CVS HEALTH Corp","filed_at":"2026-08-05T10:32:06+00:00","discovered_at":"2026-08-05T10:35:10.606177+00:00","generated_at":"2026-08-05T10:35:34.466948+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVS Health Q2 2026 GAAP EPS $2.31, adj EPS $2.58; raises FY guidance to $7.90-$8.10 adj EPS","bullets":["Total revenues $106.1B, up 7.3% YoY; GAAP diluted EPS $2.31 vs $0.80 prior year.","Adjusted EPS $2.58 vs $1.81 prior year; Health Care Benefits MBR improved to 87.4% from 89.9%.","Full-year 2026 guidance raised: GAAP EPS $6.84-$7.04 (from $6.24-$6.44), adj EPS $7.90-$8.10 (from $7.30-$7.50).","Cash flow from operations guidance raised to at least $11.5B from at least $9.5B; YTD cash flow $10.6B.","Health Services segment revenue up 11.5% to $51.8B; Pharmacy & Consumer Wellness prescriptions filled up 4.3%."],"urls":{"canonical":"https://secwatch.observer/filing/0000064803-26-000097","json":"https://secwatch.observer/filing/0000064803-26-000097.json","markdown":"https://secwatch.observer/filing/0000064803-26-000097.md","text":"https://secwatch.observer/filing/0000064803-26-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000097/0000064803-26-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64803/000006480326000097/cvs-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T10:35:34.466948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}